Accessibility Menu
RespireRx Pharmaceuticals logo

RespireRx Pharmaceuticals(OTC) RSPI

This security has been delisted. This page is retained for historical reference.

RespireRx Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 0.002025-11-13
RespireRx Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+28.57%USD 0.002025-11-06
1 month+63.64%USD 0.002025-10-14
3 month+80%USD 0.002025-08-15
Year to date+125%USD 0.002024-12-31
1 year+125%USD 0.002024-11-13
3 year-72.73%USD 0.012022-11-14
5 year-95.5%USD 0.042020-11-13
Since inception-100%USD 30,468.981992-05-01

RSPI News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

RSPI Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

19.21%

Return on Capital

N/A

Return on Assets

-9230.15%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$1.41M

EBITDA

-$400.71K

Operating Cash Flow

-$247.57K

Capital Expenditure

$0.00

Free Cash Flow

-$247.57K

Cash & ST Invst.

$6.36K

Total Debt

$2.78M

RespireRx Pharmaceuticals Performance Analysis

RespireRx Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
20222022-12-31USD 0N/A
RespireRx Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42022-12-31N/A
Q12023-03-31N/A
Q22023-06-30N/A
Q32023-09-30N/A
RespireRx Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -0.04N/A
20222022-12-31USD -0.04-10.5%
RespireRx Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42022-12-3135.9%
Q12023-03-31-24.0%
Q22023-06-30-29.0%
Q32023-09-3062.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2023YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

2

N/A

Net Income

-$395.50K

+14.3%

EBITDA

-$76.66K

+80.3%

Quarterly Fundamentals

Name
Q3 2023YOY CHG

Total Cash

$6.36K

+10503.3%

Total Debt

$2.78M

+8.8%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$2.78M

+8.8%

Return on Assets

-92.30%

N/A

Return on Invested Capital

13.49%

N/A

Free Cash Flow

-$100.96K

-44.4%

Operating Cash Flow

-$100.96K

-44.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VIRXViracta Therapeutics, Inc.
$0.01+0.00%
IPIXInnovation Pharmaceuticals Inc.
$0.00+0.00%
CBDGTHC Farmaceuticals, Inc.
$0.03+0.00%
BNGIBangi Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
FFord Motor Company
$14.37+0.02%
AALAmerican Airlines Group
$14.48+0.07%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.